Abdel-Fattah R, Challen C, Griffiths T R, Robinson M C, Neal D E, Lunec J
Cancer Research Unit, The Medical School, University of Newcastle upon Tyne, UK.
Br J Cancer. 1998 Jun;77(12):2230-8. doi: 10.1038/bjc.1998.371.
We have used microdissection of paraffin-embedded histological sections and polymerase chain reaction (PCR)-based direct DNA sequencing for 54 transitional cell carcinoma (TCC) of the bladder, to examine critically the association between TP53 nuclear accumulation determined by immunohistochemistry and the presence of TP53 mutations, and to examine their relationship to tumour stage and grade, as well as patient survival. There was a significant association between the presence of TP53-positive nuclei (> 10%) and a higher histological stage and grade (P = 0.0115, P = 0.0151 respectively; Fisher's exact). A significant association between TP53 gene mutations and TP53 nuclear reactivity in more than 10% of tumour cell nuclei was also observed (P = 0.0003; Fisher's exact). Mutations were detected in 18/54 (33%) cases together with the wild-type sequence when analysed from bulk frozen samples, with significant clustering of mutations in exons 7 and 8. The microdissection method distinguished more clearly between heterozygous and/or homozygous alterations of the TP53 tumour-suppressor gene, and clearly showed frequent accumulation of TP53 in the absence of mutations. When microdissecting immunonegative regions from the same paraffin sections, three out of ten samples showed the identical mutations detected in the immunopositive regions. There was a significant association between TP53 immunoreactivity in more than 50% of tumour cell nuclei and decreased survival among all patients (P = 0.0325; log-rank test). The patients with TP53 mutations showed a trend for a shorter survival period; however, the association was not statistically significant at the 95% confidence level (P = 0.132; log-rank test). In conclusion, our observations show that accumulation of TP53 occurs frequently in the absence of mutations, and that such accumulation is nevertheless associated with poor survival when it occurs in a high proportion (> 50%) of tumour cell nuclei.
我们采用石蜡包埋组织切片显微切割技术及基于聚合酶链反应(PCR)的直接DNA测序法,对54例膀胱移行细胞癌(TCC)进行研究,以严格检验免疫组织化学法测定的TP53核积聚与TP53突变存在之间的关联,并考察它们与肿瘤分期、分级以及患者生存率的关系。TP53阳性细胞核(>10%)的存在与较高的组织学分期及分级之间存在显著关联(分别为P = 0.0115,P = 0.0151;Fisher精确检验)。在超过10%的肿瘤细胞核中,还观察到TP53基因突变与TP53核反应性之间存在显著关联(P = 0.0003;Fisher精确检验)。从大量冷冻样本分析时,在18/54(33%)例中检测到突变以及野生型序列,外显子7和8中的突变明显聚集。显微切割法能更清晰地区分TP53肿瘤抑制基因的杂合和/或纯合改变,并清楚显示在无突变情况下TP53的频繁积聚。当从同一切石蜡切片显微切割免疫阴性区域时,十分之三的样本显示出在免疫阳性区域检测到的相同突变。在所有患者中,超过50%的肿瘤细胞核中TP53免疫反应性与生存率降低之间存在显著关联(P = 0.0325;对数秩检验)。TP53突变患者显示出生存期较短的趋势;然而,在95%置信水平下,该关联无统计学意义(P = 0.132;对数秩检验)。总之,我们的观察结果表明,TP53的积聚在无突变情况下频繁发生,而当这种积聚发生在高比例(>50%)的肿瘤细胞核中时,仍与生存率低相关。